A whole genome methylation analysis of systemic lupus erythematosus: Hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity

Genes and Immunity

Volumn 13, Issue 3, 2012, Pages 214-220

  Lin, S Y ^a,b   Hsieh, S C ^b   Lin, Y C ^c   Lee, C N ^b   Tsai, M H ^c   Lai, L C ^c   Chuang, E Y ^c   Chen, P C ^c   Hung, C C ^c   Chen, L Y ^c   Hsieh, W S ^b   Niu, D M ^d   Su, Y N ^b,c   Ho, H N ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

DNA hypomethylation; IL10; IL1R2; methylation array; systemic lupus erythematosus

Indexed keywords

DNA; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 2; INTERLEUKIN 10; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA METHYLATION; GENOME ANALYSIS; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; DNA METHYLATION; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERLEUKIN-1 TYPE II;

EID: 84859924136     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.74     Document Type: Article

References (36)

1. Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 317452.
2. Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003; 48: 746-756.
3. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1228-1233.
4. Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazineinduced lupus. J Immunol 2007; 179: 5553-5563.
5. Sawalha AH, Webb R, Han S, Kelly JA, Kaufman KM, Kimberly RP et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS ONE 2008; 3: e1727.
6. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-318.
7. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990; 33: 1665-1673.
8. Oelke K, Lu Q, Richardson D, Wu A, Deng C, Hanash S et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50: 1850-1860. (Pubitemid 38725098)
9. Scheinbart LS, Johnson MA, Gross LA, Edelstein SR, Richardson BC. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 1991; 18: 530-534.
10. Sawalha AH, Jeffries M, Webb R, Lu Q, Gorelik G, Ray D et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 2008; 9: 368-378. (Pubitemid 351791493)
11. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988; 140: 2197-2200. (Pubitemid 18098475)
12. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006; 176: 7143-7147. (Pubitemid 43849013)
13. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren0s syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37: 1647-1655.
14. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin- 10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379-385. (Pubitemid 26085213)
15. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393-395.
16. Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421-427. (Pubitemid 24062020)
17. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283-288. (Pubitemid 28219167)
18. Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol 2010; 22: 126-132.
19. Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci 2008; 13: 3312-3320. (Pubitemid 351594684)
20. Lourenco EV, Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med 2009; 9: 242-254.
21. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991; 147: 117-123.
22. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115: 189-195. (Pubitemid 29030384)
23. Johanneson B, Lima G, von Salome J, Alarcon-Segovia D, Alarco? n-Riquelme ME. A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet 2002; 71: 1060-1071. (Pubitemid 35305226)
24. Lopez P, Gutierrez C, Suárez A. IL-10 and TNFalpha genotypes in SLE. J Biomed Biotechnol 2010; 2010: 838390.
25. Nath SK, Harley JB, Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005; 118: 225-234. (Pubitemid 41672084)
26. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubreva J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 2010; 20: 170-179.
27. Mellor-Pita S, Citores MJ, Castejon R, Yebra-Bango M, Tutor-Ureta P, Rosado S et al. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin Cytom 2009; 76B: 261-270.
28. al-Janadi M, al-Dalaan A, al-Balla S, al-Humaidi M, Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 1996; 16: 198-207. (Pubitemid 26249184)
29. Murakawa Y, Takada S, Ueda Y, Suzuki N, Hoshino T, Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol 1985; 134: 187-195. (Pubitemid 15191496)
30. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461-466.
31. Zhao M, Tang J, Gao F, Wu X, Liang Y, Yin H et al. Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 931018.
32. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov 2004; 3: 1036-1046. (Pubitemid 39642366)
33. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
34. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA. Genomewide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics 2010; 3: 33.
35. Bibikova M LJ, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson K. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 2009; 1: 177-200.
36. Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS One 2010; 5: e12197.